Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Tumor microenvironment drives drug resistance in lung cancer subtypes

15

Jun 2026

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

Synthetic cooling agents in e-cigarettes link to abnormal heartbeats

15

Jun 2026

Synthetic cooling agents in e-cigarettes link to abnormal heartbeats

Synthetic cooling ingredients added to e-cigarettes caused abnormal heartbeats (arrhythmias) and increased cardiovascular risk measures in mice and lab-grown human heart cells, according to new independent research published today in Circulation: Arrhythmia and Electrophysiology, a peer-reviewed journal of the American Heart Association.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.